295 studies found for:    Open Studies | "Carcinoma, Renal Cell"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Renal Cell"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Immunotherapy Study for Metastatic Renal Cell Cancer
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Clear-cell Renal Cancer;   Recurrent Renal Cell Carcinoma;   Refractory Renal Cell Carcinoma;   Metastatic Kidney Cancer
Intervention: Biological: HyperAcute®-Renal (HAR) Immunotherapy
2 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
3 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
4 Recruiting A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Kidney Diseases;   Kidney Neoplasms;   Urogenital Neoplasms;   Urologic Diseases;   Urologic Neoplasms;   Neoplasms;   Neoplasms by Histologic Type;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Combination of varlilumab and sunitinib
5 Recruiting Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY 43-9006)
6 Not yet recruiting Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib
Conditions: Advanced Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: Sunitinib;   Drug: Isoquercetin;   Drug: Placebo
7 Not yet recruiting Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
Condition: Carcinoma, Renal Cell
Interventions: Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Sorafenib;   Drug: Pazopanib;   Drug: Everolimus;   Drug: Axitinib
8 Unknown  Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Device: DCE-MRI and Quantitative Doppler Ultrasound
9 Recruiting Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib followed by everolimus
10 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Conditions: Carcinoma of the Collecting Ducts of Bellini;   Papillary Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Intervention: Drug: Pazopanib Hydrochloride
11 Recruiting Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Drug: MK-3475
12 Recruiting Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Pathology;   Treatment Outcome;   Hemoglobin A1c Protein, Human
13 Not yet recruiting A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Interventions: Radiation: Stereotactic Radiosurgery;   Drug: Pazopanib Hydrochloride
14 Not yet recruiting Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
15 Recruiting Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Metastatic Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: Aldesleukin;   Procedure: Computed Tomography;   Drug: Entinostat;   Radiation: Fludeoxyglucose F-18;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Positron Emission Tomography
16 Recruiting A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
Conditions: ccRCC;   RCC;   Kidney Cancer;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: PT2385 Tablets
17 Unknown  Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Conditions: Clear-cell Renal Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
18 Recruiting Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer
Interventions: Biological: Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
19 Recruiting Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
Conditions: Metastatic Renal Cell Cancer;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Radiation: Stereotactic Body Radiation Therapy
20 Recruiting Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
Interventions: Drug: Vandetanib;   Drug: Metformin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years